tbuckley/cabot-search huggingface dataset:
Copper transporter CTR1 expression and tissue platinum concentration in NSCLC.
Authors: Deepak Kilari, XiMing Tang, Chi-Wan Chow, Junya Fujimoto, Neda Kalhor, Stephen Swisher, Ignacio Ivan Wistuba, David J. Stewart, Zahid Hussain Siddik, Eric S. Kim
Journal: Journal of Clinical Oncology (2013)

2601 Background: Platinum (Pt) resistance is a major limitation in the treatment of advanced non-small cell lung cancer (NSCLC). We previously demonstrated that low tissue Pt concentration in NSCLC tumor specimens was significantly associated with reduced tumor response and worse survival. Furthermore, low expression of the copper transporter CTR1, a transporter of Pt uptake is reported to be associated with poor clinical outcome following Pt-based therapy in NSCLC patients. However, a defect in CTR1expression as a causative factor in reduced Pt accumulation in NSCLC tissues is not well-established. We investigated the relationship between tissue Pt concentrations and CTR1 expression in NSCLC specimens. Methods: We identified paraffin-embedded NSCLC tissue blocks from 30 patients who underwent neoadjuvant Pt-based chemotherapy with known tissue Pt concentrations at MD Anderson Cancer Center. Expression of CTR1 was determined by immunohistochemistry with adequate controls; 0 = undetectable; 1+ = barely detectable staining; 2+ = readily appreciable staining; and 3+ = dark brown staining. Pt concentration was compared between different CTR1 expression groups. Results: Tissue Pt concentration significantly correlated with tumor response in 30 patients who received neoadjuvant Pt-based chemotherapy (P&lt;0.001). There was an uneven distribution of CTR1 expression scores with a majority of specimens demonstrating scores of 2+ (N=15, 50%). There were 2 specimens with no detectable CTR1 expression (score of 0) and 6 patients with a score of 3+. Patients with undetectable CTR1 expression in their tumors had significantly lower Pt concentrations compared to those with scores of 3+ (P=0.014). Furthermore, those with undetectable CTR1 expression had reduced tumor response compared to those with scores of 3+ following Pt-based chemotherapy (P=0.039). Conclusions: To the best of our knowledge, this is the first study to correlate CTR1 expression in clinical specimens to both tumor Pt uptake and response. Patients with undetectable CTR1 expression in their tumors had significantly lower Pt concentration and reduced tumor response. Further evaluation with a larger sample size is required. (Supported by 2012 ASCO Young Investigator Award)
CARDIAC MAGNETIC RESONANCE IMAGING AFTER RADIOFREQUENCY ABLATION OF VENTRICULAR ARRHYTHMIAS IN HUMAN PATIENTS: DEFINING THE SUBSTRATE AND VISUALIZING THE OUTCOME
Authors: Borislav Dinov, Sabrina Oebel, Sebastian Hilbert, Susanne Loebe, Arash Arya, Andreas Bollmann, Gerhard Hindricks, Cosima Jahnke, Ingo Paetsch
Journal: Journal of the American College of Cardiology (2017)
Frequency of cognitive impairment (CI) in elderly patients (pts) suffering from malignancies and impact on therapeutic decision.
Authors: Thibault De La Motte Rouge, Pascal Chaïbi, Stéphane Vignot, Helene Boussion, Luc Cabel, Romain Geiss, Francois-Michel Delgado, David Khayat, Amale Chebib, Jean-Philippe Spano
Journal: Journal of Clinical Oncology (2012)

6110 Background: Therapeutic decision remains complex when a cancer is diagnosed in elderly pts. Our aim was to evaluate the frequency of CI in this population and its impact on therapeutic decision. Methods: An oncogeriatric evaluation including Comprehensive Geriatric Assessment (CGA) is systematically performed for all elderly cancer pts referred in our unit. We reviewed data of all pts assessed by geriatric oncologist at our institution from January 2009 to June 2011. Results: 378 pts were identified, among them a CI was noted in 87. Median age was 84 years (range 71 –94), 70 % ≥ 80 years. Most of the pts (78/87) were referred at the time of diagnosis. Metastatic disease was diagnosed in 32 pts (52%) and Diffuse Large B Cell Lymphoma stage III or IV in 21 pts (81 %). In 41 pts, CI was already diagnosed: Alzheimer disease (AD) (n=38) and Vascular Dementia (n=3). CGA help to identify CI in 46 additional pts: AD (n=36); Vascular Dementia (n=2) and Mild Cognitive Impairment (n=8). 45/87 pts (52 %) were dependant for at least one activity of daily living (ADL). As a result of CGA and benefit/risk oncologic assessment, best supportive care was recommended in 12 pts. Among them, only 4 pts presented with advanced metastatic disease (main reason for palliative care). Pts in whom “best supportive care” decision (n=12) was recommended were more dependants than those who received specific anticancer therapy (n=75): dependence for at least 2 ADL: 10/12 pts (83%) versus 16/75 (21%); and presented more AD already diagnosed (11/12 versus 30/75). In the remaining 75 pts, specific cancer therapy was proposed, including chemotherapy (n=67), surgery (n=5), radiotherapy (n=3) and hormonotherapy (n=9). Treatment was initiated as recommended in all but 4 pts (best supportive care decision taken following discussion with pts and relatives). During the follow-up, only 11/75 pts needed to be placed in nursing home because of loss of autonomy. A survival ≥ 1 year was observed in 27/75 (36%) pts. An update of cognitive performance will be presented. Conclusions: Our data support that even if CI is frequent in elderly pts with malignancies, specific anticancer therapy remains feasible and should be considered in most elderly pts with CI.
Effect of microscopic residual tumor (MRT) at surgical margin of resection (SMR) in invasive breast cancer (IBC) on survival of non-Hispanic white women in central Pennsylvania (PA)
Authors: A. M. Ingle, P. Kumar, B. Baney, K. Day, T. Dagen, A. S. Galley, R. H. Dixon
Journal: Journal of Clinical Oncology (2006)

10569 Background: Few studies that have investigated the long-term effect of MRT in IBC, have demonstrated conflicting results. Mount Nittany Medical Center (MNMC) is located in an agricultural, ethnically-homogenous (Non-Hispanic White) county in PA. To the best of our knowledge, there have been no similar studies conducted on such populations. Our study has investigated the effect of MRT at SMR on overall survival (OS) and event-free survival (EFS) of patients with IBC. Methods: All women diagnosed with IBC from 04/1992 to 06/2005 at MNMC were deemed eligible. Log-rank statistics and Cox proportional hazard models (CPHM) were used for obtaining survival rates. Results: Of the 939 eligible women analysis were performed on 651 women (age range 27–94 years; median 62 years) with complete data on diagnosis, surgical margins and treatment modalities. With a median follow-up time of 4 years (range 0.01–11.3 years), 390 (59.9%), 214 (32.8%), 47 (7.2%) women had stage I, II and III tumor respectively; 540 (83%) patients had no residual tumor at SMR. 484 (74.4%) patients received radiation therapy (RT) ± chemotherapy (CT) and/or hormonal therapy (HT), 383 (58.8%) received HT ± CT and/or RT and 229 (35.2%) received CT ± RT and/or HT. The CPHM demonstrated no statistical significance of MRT on OS (hazard ratio 1.54, p = 0.07), and EFS (hazard ratio = 1.54, p = 0.07) after adjusting for treatment, stage and age. Univariate 10-year OS rate in patients with no MRT was 72.7% (95% confidence interval (CI) 63.1% to 80.1%), versus 61.2% (95% CI 45.3% to 73.8%) in patients with MRT (p-value = 0.07). Ten-year EFS was observed to be 68.9% (95% CI 59.1% to 76.8%) in patients with no MRT, versus 60.8% (95% CI 45.1% to 73.2%) in patients with MRT (p-value = 0.08). Conclusion: In our study, patients with IBC with MRT at SMR have a 1.5 times the risk of death or recurrence as compared to patients with no MRT. However, this difference is statistically not significant over time. No significant financial relationships to disclose.
T1 MAPPING IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION DETECTS INCREASED INTERSTITIAL MYOCARDIAL FIBROSIS AND ASSESSES THE SEVERITY OF HEART FAILURE
Authors: Allen Weiss, Juan Antonio Requena Ibanez, Chirag Agarwal, Rebecca Smoller, Johanna Contreras, Jagat Narula, Valentin Fuster, Juan Badimon, Angel Sanz Salvo, Carlos Santos-Gallego, Mount Sinai
Journal: Journal of the American College of Cardiology (2017)
THE CARDIAC MYOSIN ACTIVATOR, OMECAMTIV MECARBIL, IMPROVES LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN CHRONIC HEART FAILURE (COSMIC-HF)
Authors: Tor Biering-Sorensen, John Teerlink, G. Michael Felker, John McMurray, Fady Malik, Narimon Honarpour, Maria Laura Monsalvo, James Johnston, Scott D. Solomon
Journal: Journal of the American College of Cardiology (2017)
Transethnic meta-analysis identifies<i>GSDMA</i>and<i>PRDM1</i>as susceptibility genes to systemic sclerosis
Authors: Chikashi Terao, Takahisa Kawaguchi, Philippe Dieude, John Varga, Masataka Kuwana, Marie Hudson, Yasushi Kawaguchi, Marco Matucci-Cerinic, Koichiro Ohmura, Gabriela Riemekasten, Aya Kawasaki, Paolo Airo, Tetsuya Horita, Akira Oka, Eric Hachulla, Hajime Yoshifuji, Paola Caramaschi, Nicolas Hunzelmann, Murray Baron, Tatsuya Atsumi, Paul Hassoun, Takeshi Torii, Meiko Takahashi, Yasuharu Tabara, Masakazu Shimizu, Akiko Tochimoto, Naho Ayuzawa, Hidetoshi Yanagida, Hiroshi Furukawa, Shigeto Tohma, Minoru Hasegawa, Manabu Fujimoto, Osamu Ishikawa, Toshiyuki Yamamoto, Daisuke Goto, Yoshihide Asano, Masatoshi Jinnin, Hirahito Endo, Hiroki Takahashi, Kazuhiko Takehara, Shinichi Sato, Hironobu Ihn, Soumya Raychaudhuri, Katherine Liao, Peter Gregersen, Naoyuki Tsuchiya, Valeria Riccieri, Inga Melchers, Gabriele Valentini, Anne Cauvet, Maria Martinez, Tsuneyo Mimori, Fumihiko Matsuda, Yannick Allanore
Journal: Annals of the Rheumatic Diseases (2017)

Systemic sclerosis (SSc) is an autoimmune disease characterised by skin and systemic fibrosis culminating in organ damage. Previous genetic studies including genome-wide association studies (GWAS) have identified 12 susceptibility loci satisfying genome-wide significance. Transethnic meta-analyses have successfully expanded the list of susceptibility genes and deepened biological insights for other autoimmune diseases.We performed transethnic meta-analysis of GWAS in the Japanese and European populations, followed by a two-staged replication study comprising a total of 4436 cases and 14 751 controls. Associations between significant single nuclear polymorphisms (SNPs) and neighbouring genes were evaluated. Enrichment analysis of H3K4Me3, a representative histone mark for active promoter was conducted with an expanded list of SSc susceptibility genes.We identified two significant SNP in two loci, GSDMA and PRDM1, both of which are related to immune functions and associated with other autoimmune diseases (p=1.4×10-10 and 6.6×10-10, respectively). GSDMA also showed a significant association with limited cutaneous SSc. We also replicated the associations of previously reported loci including a non-GWAS locus, TNFAIP3. PRDM1 encodes BLIMP1, a transcription factor regulating T-cell proliferation and plasma cell differentiation. The top SNP in GSDMA was a missense variant and correlated with gene expression of neighbouring genes, and this could explain the association in this locus. We found different human leukocyte antigen (HLA) association patterns between the two populations. Enrichment analysis suggested the importance of CD4-naïve primary T cell.GSDMA and PRDM1 are associated with SSc. These findings provide enhanced insight into the genetic and biological basis of SSc.
Transcriptional Landscape of APL Identifies Aberrant Podoplanin Expression As a Defining Feature and Missing Link for the Bleeding Disorder of This Disease
Authors: Vincent-Philippe Lavallée, Miriam Marquis, Marie-Ève Bordeleau, Jalila Chagraoui, Tara MacRae, Isabel Boivin, Geneviève Boucher, Patrick Gendron, Sébastien Lemieux, Arnaud Bonnefoy, Georges E. Rivard, Josée Hébert, Guy Sauvageau
Journal: Blood (2016)
THE USE OF MAGNETIC RESONANCE IMAGING WITH FERUMOXYTOL FOR ANNULUS SIZING IN PATIENTS WITH CHRONIC KIDNEY DISEASE UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Sanjum S. Sethi, William Suh, Kathryn Cardoza, Murray Kwon, Richard Shemin, J. Paul FInn, Gabriel Vorobiof, Eric Yang, Olcay Aksoy
Journal: Journal of the American College of Cardiology (2017)
EFFECTS OF INDUCTION BEFORE VENTRICULAR TACHYCARDIA ABLATION ON LONG-TERM SUCCESS RATE
Authors: Pouria Alipour, Yaariv Khaykin, Zahra Azizi, Amirhossein Sharifzad, Despina Michailidis, Patrick Mallany, Evan Michaelov, Nikhil Nath, Alfredo Pantano, Atul Verma
Journal: Journal of the American College of Cardiology (2017)
NINE YEAR TRENDS IN CAUSE-SPECIFIC MORTALITY AFTER PERCUTANEOUS CORONARY INTERVENTION: OBSERVATIONS FROM THE ALBERTA PROVINCIAL PROJECT FOR OUTCOME ASSESSMENT IN CORONARY HEART DISEASE (APPROACH) REGISTRY
Authors: Walid Barake, Dat Tran, Diane Galbraith, Colleen Norris, Merril L. Knudtson, Padma Kaul, Finlay McAlister, Roopinder Sandhu
Journal: Journal of the American College of Cardiology (2017)
Early peritoneal dialysis reduces lung inflammation in mice with ischemic acute kidney injury
Authors: Chris Altmann, Nilesh Ahuja, Carol M. Kiekhaefer, Ana Andres Hernando, Kayo Okamura, Rhea Bhargava, Jane Duplantis, Lara A. Kirkbride-Romeo, Jill Huckles, Benjamin M. Fox, Kashfi Kahn, Danielle Soranno, Hyo-wook Gil, Isaac Teitelbaum, Sarah Faubel
Journal: Kidney International (2017)

Although dialysis has been used in the care of patients with acute kidney injury (AKI) for over 50 years, very little is known about the potential benefits of uremic control on systemic complications of AKI. Since the mortality of AKI requiring renal replacement therapy (RRT) is greater than half in the intensive care unit, a better understanding of the potential of RRT to improve outcomes is urgently needed. Therefore, we sought to develop a technically feasible and reproducible model of RRT in a mouse model of AKI. Models of low- and high-dose peritoneal dialysis (PD) were developed and their effect on AKI, systemic inflammation, and lung injury after ischemic AKI was examined. High-dose PD had no effect on AKI, but effectively cleared serum IL-6, and dramatically reduced lung inflammation, while low-dose PD had no effect on any of these three outcomes. Both models of RRT using PD in AKI in mice reliably lowered urea in a dose-dependent fashion. Thus, use of these models of PD in mice with AKI has great potential to unravel the mechanisms by which RRT may improve the systemic complications that have led to increased mortality in AKI. In light of recent data demonstrating reduced serum IL-6 and improved outcomes with prophylactic PD in children, we believe that our results are highly clinically relevant.
HOSPITAL ADMISSIONS FOR CHEST PAIN ASSOCIATED WITH COCAINE USE IN THE UNITED STATES
Authors: Alexis Rodriguez, Vikas Singh, Ghanshyambhai Savani, Badal Thakkar, Nileshkumar Patel, Carlos Alfonso, Mauricio Cohen, Raul Mitrani, Juan Viles-Gonzalez, Jeffrey Goldberger
Journal: Journal of the American College of Cardiology (2017)
CARDIOVASCULAR OUTCOMES WITH NEBIVOLOL, ATENOLOL AND METOPROLOL IN PATIENTS WITH HYPERTENSION: A LARGE, RETROSPECTIVE, PROPENSITY SCORE-MATCHED COHORT STUDY
Authors: Brent Egan, Alan Gradman, Sanjida Ali, Qian Li, Mehul Patel, Jan Basile
Journal: Journal of the American College of Cardiology (2017)
Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients
Authors: Mrinal M. Patnaik, Curtis A. Hanson, Janice M Hodnefield, Terra L Lasho, Christy Finke, Ryan A Knudson, Rhett P Ketterling, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2011)
COLCHICINE EXERTS ANTITHROMBOTIC PROPERTIES IN OXLDL-TREATED ENDOTHELIAL CELLS VIA INHIBITION OF TISSUE FACTOR EXPRESSION AND ACTIVITY
Authors: Giovanni Cimmino, Stefano Conte, Andrea Morello, Grazia Pellegrino, Giovanni Ciccarelli, Michele De Paulis, Plinio Cirillo, Paolo Golino
Journal: Journal of the American College of Cardiology (2017)
Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group
Authors: Robyn M. Scherber, Holly Geyer, Heidi E. Kosiorek, Amylou C. Dueck, Jean-Jacques Kiladjian, Stefanie Slot, Sonja Zweegman, Peter Te Boekhorst, Suzan Commandeur, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, Heike L Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Doehner, Thomas Lehmann, Karen Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N. Harrison, Deepti Radia, Pablo J. Muxi, Norman I Maldonado, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Bjorn Andreasson, Maria Ferrari, Alessandro Rambaldi, Jan Samuelsson, Keith Cannon, Xiujuan Sun, Junqing Xu, Peihong Zhang, Zefeng Xu, Ruben A. Mesa
Journal: Blood (2016)
Patients (pts) understanding of phase II trial designs and informed consent (IC)
Authors: S. D. Undevia, F. J. Hlubocky, B. C. Goh, M. J. Ratain, C. K. Daugherty
Journal: Journal of Clinical Oncology (2004)

6011 Background: Phase II trials determine disease-specific activity of new agents. Standard phase II designs enroll initial cohorts, and the trial is terminated if all subjects are non-responders (NR). Due to ethical and scientific concerns, it is difficult to know if available NR information should be part of subject IC. Thus, we sought pts' understanding of the design and goals of phase II trials, experiences with IC, and interest in NR information. Methods: We conducted semi-structured interviews of cancer pts who recently enrolled in phase II trials at our institution. Results: Fifty-two of 54 consecutive pts agreed to be interviewed: 73% male, median age 58 (35–83), 77% white, 56% with some college. Patients reported physician phase II goals as: therapeutic benefit short of cure (60%), scientific (25%), cure/remission (20%). Patients own goals were prolongation of life (38%), therapeutic benefit short of cure (37%), cure/remission (23%). With regard to IC, 85% said they were told that advancement of scientific knowledge was an aspect of the trial, 79% said they were told they could stop treatment at any time, and 96% said they were informed of possible side effects; 73% said they were well informed of other options. However, only 50% of these pts reported they were offered non-experimental therapy, 32% no chemotherapy, and 12% palliative therapy. When asked about their understanding of the principal purpose of a phase II trial, 48% responded that it was therapeutic benefit short of cure, 40% advancement of scientific knowledge, 24% disease cure. Patients were also asked to define a threshold number (T) of NR they would be willing to accept before refusing enrollment. A majority (72%) was able to define a T: median 6.5 (1–99); and of these, 72% responded with a T that was <14 (cohort size required to detect a 20% RR). Seventy-four percent said they would want NR information before consenting to treatment; and 83% of these thought this information should be in the written consent form. Conclusions: Our data suggest that pts may not be adequately informed of alternatives to phase II trials and that disclosure of prior NR information is important to pts and may impact enrollment decisions. No significant financial relationships to disclose.
Identification of differentially expressed genes in hepatocellular carcinoma using representational difference analysis
Authors: K. U. Park, H.-M. Ryoo, D. Y. Zang
Journal: Journal of Clinical Oncology (2004)

9700 Background: Hepatocellular carcinome (HCC) is a primary malignant neoplasm of the liver found throughout the world and is especially prevalent where the incidences of chronic hepatitis B (HBV) and C (HCV) are high. Molecular approaches have recently revealed involvement of the genes such as p53, p21, p27, p73, p16, pRb, pTEN, and MAGE have been demonstrated to be associated with HCC. However, the molecular mechanism of HCC carcinogenesis and development still remains to be elucidated. In this study, to identify the genes specifically expressed in HCC, subtractive library using representational difference analysis (RDA) coupled to microarray hybridization was applied to HCC and background liver tissues. Methods: Primary HCC and corresponding noncancerous liver tissues were obtained with informed consent from 5 patients who underwent hepatectomy. To identify differentially expressed genes in human HCC, subtractive library by RDA was constructed in HCC and the corresponding background liver tissue. After TA cloning and random selection of subtractive library clones, they were used for microarray hybridization. Results: After screening, more than 50 HCC specific gene fragments were identified, including alpha fetoprotein, glypican-3, preferentially expressed antigen in melanoma (PRAME), fucosidase alpha, carcinoembryonic antigen (CEA), and topoisomerase II. We further characterized one of differentially expressed gene, glypican 3. In situ hybridization showed that glypican 3 was moderate to intensely expressed in HCC but not in normal hepatocytes. Northern blot and RT-PCR of glypican 3 gene in 7 hepatocellular/hepatoblastoma cell lines showed, HepG2 cells express high levels and Hep3B and SNU368 cells express moderate to low levels of glypican 3. Conclusions: Glypican 3 is specifically expressed in HCC and is a cell surface protein, it can be a useful diagnostic marker and be a good target molecule for gene therapy or immunotherapy in HCC. No significant financial relationships to disclose.
ASSESSMENT OF MYOCARDIAL PERFUSION RESERVE INDEX USING ADENOSINE VERSUS REGADENOSON AMONG HEALTHY FEMALE SUBJECTS
Authors: Sawan Jalnapurkar, Parham Zarrini, Janet Wei, Behzad Sharif, Balaji Tamarappoo, Ahmed Al Badri, Galen Cook-Wiens, Daniel Berman, Louise Thomson, C. Noel Bairey Merz
Journal: Journal of the American College of Cardiology (2017)
RELATIONSHIP BETWEEN OPTICAL COHERENCE TOMOGRAPHY-DEFINED IN-STENT NEOATHEROSCLEROSIS AND OUT-STENT ARTERIAL REMODELING ASSESSED BY SERIAL INTRAVASCULAR ULTRASOUND EXAMINATIONS IN LATE AND VERY LATE DRUG-ELUTING STENT FAILURE
Authors: Makoto Araki, Taishi Yonetsu, Tadashi Murai, Yoshihisa Kanaji, Eisuke Usui, Masahiro Hoshino, Masahiro Hada, Takayuki Niida, Rikuta Hamaya, Sadamitsu Ichijo, Yoshinori Kanno, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2017)
Psychosomatic Assessment and Integrative Care: 22nd World Congress on Psychosomatic Medicine Lisboa, September 1214, 2013
Journal: Psychotherapy and Psychosomatics (2013)

Introduction: post-partum depression (PPD) is a prevalent disorder (10-15%).This study aims to contribute to the research on PPD risk factors in a Chilean sample and compare them with a similar Spanish group.Methods: prospective study, a sample of 200 Chilean puerperal women was compared with a 309 Spanish similar group.Immediate PP evaluation included demographics, history of pregnancy and childbirth, presence of depression (EPDS -DIGS), anxiety (STAI), neuroticism, coping strategies (COPE), stressful recent and previous life events (St Paul Ramsey -ETI) and social support.Evaluation at follow-up (8 to 32 weeks) included depression (EDPS -DIGS) and anxiety (STAI).Results: in both studies, the number and the intensity of stressful events during pregnancy, the personal psychiatric history, and the emotional alterations during pregnancy and immediate post-partum were associated with depression in the immediate post-partum.In the Spanish sample familiar psychiatric precedents were also associated with the latter.In relation with PPD in the Chilean sample, depressive symptoms in the immediate post-partum, the family history of PPD, and multiple births were related.In the Spanish sample there was an association between PPD and depressive symptoms during the immediate post-partum, between the personal history of psychiatric disorders and PPD, depressive symptoms during pregnancy, unplanned pregnancy and number of stressful events during it.Conclusions: similar risk factors for depression in the immediate post-partum and PPD were observed in both samples.Future studies should focus in the development of new intervention strategies for PPD.